Search

Displaying results 6531 - 6540 of 10000 in total
  1. Drug

    Streptococcus pneumoniae type 33f capsular polysaccharide antigen

    go.drugbank.com/drugs/DB10341
    ApprovedInvestigational

    Streptococcus pneumoniae type 33f capsular polysaccharide antigen is a vaccine that contains highly purified capsular polysaccharides from the invasive pneumococcal type 33f of *Streptococcus pneumoniae

  2. Drug

    VIR-5818

    go.drugbank.com/drugs/DB28582
    Investigational

    VIR-5818 is under investigation in clinical trial NCT05356741 (To Access the Safety and Effects of Intravenous Administration of VIR-5818 Alone and in Combination With Pembrolizumab in Adult Participants

  3. Drug

    Tarenflurbil

    go.drugbank.com/drugs/DB05289
    Investigational

    Aβ42 is the primary initiator of neurotoxicity and amyloid plaque development in the brains of Alzheimer's disease patients. … In June 2008 development of the drug for Alzheimer's disease was discontinued. Tarenflurbil has also been used in trials studying the treatment of Prostate Cancer.

  4. Drug

    Interferon Gamma

    go.drugbank.com/drugs/DB15753
    Investigational

    The interferon is primarily produced by activated T lymphocytes and natural killer cells. … Interferon gamma is a Type 1 inflammatory cytokine and the only type II interferon. It has antitumor properties, antiviral activities, and important immunoregulatory functions.

  5. Drug

    Chlorfenson

    go.drugbank.com/drugs/DB05377
    Experimental

    Chlorfenson is developed by Moberg Derma for the treatment of onychomycosis (nail fungus) as the primary indication.

  6. Drug

    EGEN-001

    go.drugbank.com/drugs/DB05953
    Investigational

    EGEN-001 is a novel non-viral vector consisting of a plasmid DNA encoding the human gene for interleukin 12 (IL-12) and a biocompatible, biodegradable delivery polymer with potential antineoplastic activity

  7. Drug

    T-5224

    go.drugbank.com/drugs/DB05998
    Experimental

    T-5224 is an investigational drug developed to treat Sepsis-induced Acute Kidney Injury. It's mechanism of action is to inhibit c-Fos/activator protein-1.

  8. Drug

    Rexin G

    go.drugbank.com/drugs/DB16450
    Investigational

    Rexin-G is a tumor-targeted, injectable retroviral vector carrying a mutant form of the cyclin G1 gene. … It is under development by Epeius Biotechnologies for the potential treatment of metastatic cancer. It is also being investigated for preventing SARSCOV-2 viral entry.

  9. Drug

    AOD9604

    go.drugbank.com/drugs/DB06388
    Experimental

    AOD9604 is a synthetic analogue of the lipolytic domain of human growth hormone, being investigated for the treatment of obesity.

  10. Drug

    Etazolate

    go.drugbank.com/drugs/DB05881
    Investigational

    EHT 0202 is developed to treat neurodegenerative disorders by ExonHit Therapeutics.